CytoDyn Announces Collaboration With Dr. Bruce Torbett, The Scripps Research Institute, to Study PRO 140 in a Pre-exposure Prophylaxis (PrEP) Model of HIV Infection

PORTLAND, Ore.--(BUSINESS WIRE)--CytoDyn Inc. (“CytoDyn”) (OTC QB: CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, announced today that it has entered into a research collaboration with Dr. Bruce Torbett of The Scripps Research Institute to study CytoDyn's experimental humanized anti-CCR5 antibody PRO 140 in a pre-exposure prophylaxis (PrEP) model of HIV infection. The purpose of this study is to assess the potential for the use of PRO 140 to prevent HIV infection. “Published clinical data has demonstrated that PRO 140 has anti-viral activity. We believe that it is an important next step for the company to investigate the possibility that PRO 140 might have a role in HIV prevention,” commented Dr. Nader Pourhassan, CytoDyn’s President and CEO.

Back to news